City uses high tech solutions to address traffic safety
Calgary is investing around $10,000 to integrate technology into its current traffic management system
Drones, virtual reality headsets and artificial intelligence (AI) are now part of the City of Calgary's operations at the traffic management centre, a first in Canada.
Investing about $10,000 to integrate the technology with its current system, city officials hope to add more gear to monitor even more intersections and improve traffic flow and pedestrian safety.
'It gives our techs and technicians and engineers more information, more real-time information to make decisions in a real-time manner,' said Ravi Seera, acting director of mobility with the City of Calgary.
'We are looking at expanding to 10 to 15 intersections next year primarily around high pedestrian areas.'
It's current system manages 1,300 intersections with 200 cameras.
Drone coverage
The city is also using drones to monitor traffic backups.
Traffic drone, Calgary, June 18, 2025
The City of Calgary is using drones to improve its traffic management.
(Stephanie Thomas, CTV Calgary)
Each drone cost about $1,000 and weighs less than a sandwich.
Technicians can literally get a birds-eye vantage point which helps inform decisions about where and when to change the traffic lights and alleviate backups.
A-I is also being used to collect data about road usage, but not about motorists, pedestrians and cyclists.
'Anything we can do that helps people get around better, easier and save time in their day, we are absolutely going to deploy every type of technology to make that happen,' said Calgary Mayor Jyoti Gondek, Mayor of Calgary.
Gondek said this data can help inform officials about areas where road improvements are needed and where infrastructure upgrades will be useful.
Road safety
The Alberta Motor Association (AMA) also used AI to complete a study about road safety to identified high-risk near-miss incidents, and reports there's more than one close call in Canada ever single day.
Over seven months ending in February 2025, the report found one in every 770 pedestrians and one in every 500 cyclists were almost hit to a severity that would have caused serious injury or death.
'That's where we encourage municipalities to use this real-time data, where some of these near-misses and close calls and perception issues that are reported in by the community are real,' said Dominic Schumuhn, manager of advocacy for the AMA.
Calgary Mobility officials add that no other municipality in the world is supplying images and data to Google Images and Google maps, which will also help update navigation apps.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Why Plains All American Pipeline Stock Was a Winner on Wednesday
Plains All American Pipeline (NASDAQ: PAA) stock was the pipeline to increased gains for investors on Wednesday. They traded the shares up by nearly 4% on news of an important divestment, and that rate easily beat the essentially flat-lining S&P 500 index. Selling the Canadian NGL business After market close on Tuesday, Plains and its majority owner, Plains GP Holdings (NASDAQ: PAGP), disclosed that they had finalized agreements to sell "substantially all" of their natural gas liquids (NGL) business. The acquirer is a Canadian peer company, Keyera, and the deal is to be effected in cash. The price is roughly 5.15 billion Canadian dollars ($3.79 billion). The sale is expected to close in the first quarter of 2026, subject to the applicable regulatory approvals and closing conditions. Plains added that, accounting for a potential one-time "special distribution" estimated at $0.35 per unit to both Plains common unit holders and Plains GP shareholders, it will reap total proceeds of around $3 billion from the divestment. The special distribution payment is subject to approval by Plains's board of directors. Following the sale, Keyera will own Plains' Canadian NGL assets, but Plains will retain those in its native U.S. The latter company's crude oil assets in Canada are not part of the deal. A win-win, says the seller In its press release on the deal, Plains quoted CEO Willie Chiang as saying that it's "a win-win transaction for both Plains and Keyera. Plains is exiting the Canadian NGL business at an attractive valuation while Keyera is receiving highly complementary and critical infrastructure in a strategic market." Judging by their collective reaction, Plains investors agree with this assessment. It will provide the company with gobs of capital while slimming its operational structure and allowing it to concentrate more on the crude oil segment. Should you invest $1,000 in Plains All American Pipeline right now? Before you buy stock in Plains All American Pipeline, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Plains All American Pipeline wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $658,297!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $883,386!* Now, it's worth noting Stock Advisor 's total average return is992% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
an hour ago
- Globe and Mail
Ascot Announces Results of Annual General Meeting Held June 18, 2025
VANCOUVER, British Columbia, June 18, 2025 (GLOBE NEWSWIRE) -- Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (' Ascot ' or the ' Company ') reports that at its annual general meeting (the " AGM") held on June 18, 2025, Ascot's Shareholders approved by majority: to set the number of directors at six (6), to elect all six directors standing for election; to re-appoint PricewaterhouseCoopers LLP as the Company's auditor; and the philosophy and design of the Company's executive compensation. Detailed results of the votes held by ballot at the AGM are set out below: Total Votes Cast For Total Votes Cast Against % For % Against Number of Directors 669,702,396 248,142,848 72.96 27.04 Nominee Total Votes Cast For Total Votes Withheld % For % Withheld Stephen Altmann 914,787,147 3,058,097 99.67 0.33 William Bennett 667,932,279 249,912,965 72.77 27.23 James Currie 669,252,482 248,592,762 72.92 27.08 Indi Gopinathan 668,365,101 249,480,143 72.82 27.18 José Marún 915,443,084 2,402,160 99.74 0.26 Andree St-Germain 915,172,848 2,672,396 99.71 0.29 Total Votes Cast For Total Votes Withheld % For % Withheld Appointment of Auditors 917,384,113 461,131 99.95 0.05 Total Votes Cast For Total Votes Cast Against % For % Against Approval of Unallocated Entitlements under the Stock Option Plan 906,825,981 11,019,263 98.80 1.20 Approval of Unallocated Entitlements under the Share Unit Plan 909,443,156 8,402,088 99.08 0.92 Approval of Unallocated Entitlements under the DSU Plan 909,647,805 8,197,439 99.11 0.89 Advisory Vote on Compensation 909,800,225 8,045,019 99.12 0.88 The Board of Directors extend their thanks to the Shareholders of the Company for their continued support. On behalf of the Board of Directors of Ascot Resources Ltd. 'James A (Jim) Currie ' CEO & COO For further information contact: KIN COMMUNICATIONS INC. Email: AOT@ Phone: 604-684-6730 About Ascot Resources Ltd. Ascot is a Canadian mining company headquartered in Vancouver, British Columbia, and its shares trade on the Toronto Stock Exchange under the ticker AOT and on the OTCQX under the ticker AOTVF. Ascot is the 100% owner of the Premier Gold Mine, which poured first gold in April 2024 and is located on Nisga'a Nation Treaty Lands, in the prolific Golden Triangle of northwestern British Columbia. For more information about the Company, please refer to the Company's profile on SEDAR+ at or visit the Company's web site at The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding Forward-Looking Information All statements and other information contained in this press release about anticipated future events may constitute forward-looking information under Canadian securities laws ("forward-looking statements"). Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "targeted", "outlook", "on track" and "intend" and statements that an event or result "may", "will", "should", "could", 'would' or "might" occur or be achieved and other similar expressions. All statements, other than statements of historical fact, included herein are forward-looking statements, including statements in respect of the leadership transaction and the ability of the Company to accomplish its business objectives. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements, including risks related to the need for future waivers or forbearance agreements from the secured creditors of the Company; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; uncertainty of estimates and projections relating to development, production, costs and expenses, and health, safety and environmental risks; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need for cooperation of government agencies and indigenous groups in the exploration and development of Ascot's properties and the issuance of required permits; the need to obtain additional financing to finance operations and uncertainty as to the availability and terms of future financing; the possibility of delay in future plans and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; and other risk factors as detailed from time to time in Ascot's filings with Canadian securities regulators, available on Ascot's profile on SEDAR+ at including the Annual Information Form of the Company in the section entitled "Risk Factors'. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Although Ascot believes that the expectations reflected in such forward-looking statements and/or information are reasonable, undue reliance should not be placed on forward-looking statements since Ascot can give no assurance that such expectations will prove to be correct. Ascot does not undertake any obligation to update forward-looking statements, other than as required by applicable laws. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Globe and Mail
2 hours ago
- Globe and Mail
Biochips Market Projected to Reach USD 37.73 Bn by 2032, Growing at 16.0% CAGR
Biochips Market, By Product Type (DNA Chips, Protein Chips, Lab-on-chip Tissue Arrays, Cell Arrays), By End User (Biotechnology and Pharmaceutical Companies, Academic & Research Institutes, Hospitals and Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) According to a recent report by Coherent Market Insights, Global Biochips market is estimated to be valued at USD 13.34 Bn in 2025 and is expected to reach USD 37.73 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.0% from 2025 to 2032. Increasing application of biochips in the field of proteomics, genomics and drug discovery can drive the market growth. Extensive R&D activities in the field of healthcare and growing demand for point-of-care testing and diagnostics can also boost demand for biochips during the forecast period. Global Biochips Market Key Takeaways According to Coherent Market Insights (CMI), the global biochips market size is projected to grow at a robust CAGR of 16%, from USD 13.34 Bn in 2025 to USD 37.73 Bn by 2032. Based on product type, DNA chips segment is expected to account for over two-fifths of the global biochips market in 2025. By end user, biotechnology and pharmaceuticals segment will likely hold a market share of 35.1% by 2025. North America is anticipated to retain its dominance, holding a market share of nearly 2/5 in 2025. As per CMIs' new biochips market analysis, Asia Pacific is expected to experience fastest growth during the forecast period. Growing Demand for Personalized Medicine Boosting Market Growth Coherent Market Insights' latest biochips market research report highlights major factors driving industry growth. One such prominent growth factor is the increasing demand for personalized medicine. Biochips are a key enabling technology in personalized medicine. They enable rapid and accurate analysis of an individual's genetic and proteomic profiles. This supports pharmacogenomics, helps in creating tailored treatment plans, and facilitates targeted therapies. These capabilities are especially valuable in managing complex diseases such as cancer. Thus, growing interest in personalized medicine will continue to provide a strong impetus for the growth of biochips market in the coming years. High Cost of Biochips and Adoption of Alternative Technologies Limiting Market Growth The future biochips market outlook looks promising. However, high cost of bioships and associated equipment, along with growing usage of alternative technologies, remain a significant barrier to broader market growth. Biochips are quite expensive due to their complex manufacturing processes and the need for specialized instrumentation. This high cost limits their accessibility, particularly among small and mid-sized laboratories, thereby reducing overall biochips market demand. Many end users are turning to alternative technologies like immunoassays, qPCR, and next-generation sequencing (NGS) due to their accuracy and cost-efficiency. This trend may also negatively impact the biochips market growth in the coming years. Growing Adoption in Disease Diagnostics Creating Lucrative Growth Opportunities Biochips are being increasingly used in the diagnosis of cancer, genetic disorders, and infectious diseases due to their high accuracy and speed. Their rising adoption in disease diagnostics is expected to create lucrative growth opportunities for biochip manufacturers during the forecast period. Rising incidence of chronic and infectious diseases, such as COVID-19, is creating a strong need for rapid diagnostics. This is expected to drive demand for biochips, as they offer fast and multiplexed detection of pathogens, making them ideal for point-of-care testing. Get Up to 25% Discount on the US Tariff Impact Analysis Report: Impact of AI on the Biochips Market Artificial Intelligence (AI) is making a profound impact on the biochips market. It enhances data analysis, diagnostics, and personalized medicine. AI algorithms significantly improve the accuracy and speed of disease detection by rapidly interpreting complex biological data produced by biochips. This powerful combination accelerates drug discovery and enables real-time health monitoring. With ongoing advancements in AI, new applications and efficiencies are expected to emerge. This evolution is poised to propel the biochips market toward greater scalability and precision in delivering advanced healthcare solutions. Emerging Biochips Market Trends Growing trend of miniaturization is significantly impacting the biochips market value. Key manufacturers are focusing on developing compact biochips (e.g. lab-on-a-chip systems) with improved features for use in diagnostics, drug discovery, and personalized medicine. Expanding applications of biochips in drug discovery is expected to foster sales growth. Biochips are increasingly used in drug discovery processes, particularly for gene expression analysis, toxicity profiling, and target identification. These applications are crucial for accelerating pharmaceutical R&D, thereby driving market growth. There is a growing emphasis on studying genes and proteins to better understand disease mechanisms, identify potential therapeutic targets, and develop personalized medicine approaches. This will likely create a strong demand for biochips in high-throughput research. Shift toward point-of-care testing (POCT) is expected to create lucrative growth avenues for biochip companies. Portable biochips are being widely used in POCT devices for faster diagnostics at the patient's location. Ongoing advancements in biochip manufacturing will also support market expansion. Improvements in microfluidics, microarray technology, and semiconductor biochip development are significantly enhancing capabilities of biochips. Analyst's View ' The global biochips market is expected to record robust growth, owing to increasing incidence of chronic and infectious diseases, rising demand for personalized medicines, and advancements in biochip manufacturing,' said senior analyst Abhijeet Kale. Current Events and Their Impact on the Biochips Market Competitor Insights Key companies listed in biochips market report: - LinguaFlex - Inspire Medical Systems, Inc. - Medtronic - LivaNova PLC - SomnoMed - Nihon Kohden Corporation - Siesta Medical Inc. - ResMed - Koninklijke Philips N.V. - Somnowell - Nyxoah SA - Fisher & Paykel Healthcare Limited - VYAIRE - Natus Medical Incorporated - Nox Medical - Drive DeVilbiss International - CLEVELAND MEDICAL DEVICES INC. - Advanced Brain Monitoring, Inc. - CONTEC MEDICAL SYSTEMS CO., LTD Key Developments In January 2025, Coherent Corp launched its new pinhole array biochips. These biochips are specifically designed for medical diagnostics, with a strong focus on gene sequencing applications. In May 2025, Archer Materials Limited partnered with Paragraf Limited for Biochip development. This partnership is intended to help Archer advance its Biochip for at-home testing of chronic kidney disease. Market Segmentation By Product Type DNA Chips Cancer Diagnosis and Treatment Gene Expression SNP Genotyping Genomics Drug Discovery Agricultural Biotechnology Others Protein Chips Proteomics Expression Profiling Diagnostics HTS Others Lab-on-chip IVD & POC Others Tissue Arrays Cell Arrays By End User Biotechnology and Pharmaceutical Companies Academic & Research Institutes Hospitals and Diagnostic Centers Others About Us:Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Media Contact Company Name: Coherent Market Insights Contact Person: Mr. Shah Email: Send Email Phone: + 12524771362 Address: 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States Burlingame City: Burlingame State: California Country: United States Website:
